Nuvalent, Inc. (NUVL)
107.61
+3.75
(+3.61%)
USD |
NASDAQ |
Apr 17, 16:00
107.64
+0.03
(+0.03%)
After-Hours: 20:00
Nuvalent SG&A Expense (Quarterly) : 34.43M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Glaukos Corp. | 94.70M |
| Edgewise Therapeutics, Inc. | 12.38M |
| Cogent Biosciences, Inc. | 23.93M |
| Neurocrine Biosciences, Inc. | 301.80M |
| Arcellx, Inc. | 31.24M |